PubMed Health⌕ Search

PubMed · 15095721

[Medications, epileptic crises, and epilepsy].

Abstract

Drug-induced seizures are an uncommon complication of drug therapy. The drug related factors are either the intrinsic epileptogenicity of the specific agent or patient related factors such as convulsive predisposition, underlying neurologic dysfunction, and factors which affect the serum concentration and/or central neurologic system concentrations. Some anti epileptic drugs may aggravate an epileptic syndrome. In 10-15% of patients with epilepsy, better control of seizures can be achieved with combination therapy. These patients are at greater risk of suffering clinically serious interactions. Drug interactions occur at the pharmacokinetic level and at the pharmacodynamic level, involving synergistic or antagonistic effects. Finally many drugs can interfere with the antiepileptic drug metabolism. The inverse effect is also frequent. A better knowledge of the spectrum of drugs that cause seizures or interfere with antiepileptic drugs metabolism is important for evaluation of appropriate treatment options and for guiding the choice of rational therapeutic procedures.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Pierre Jallon, Stephen Perrig. 2003. [Medications, epileptic crises, and epilepsy].. https://pubmed.ncbi.nlm.nih.gov/15095721/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗